CYBB and chronic granulomatous disease: A trial performed in Germany in 2004 using a gamma-retroviral vectorexpressing gp91phox under the transcriptional control of the spleenfocus-forming virus long terminal repeat (LTR) appeared to have achievedsuperior results in two CGD patients when around 15% of neutrophils were foundto be functionally corrected early after treatment.